Back

ERC-FUNDED Computational Biologist

Institute of Hematology - Hopital Saint Louis
Hematology
France Paris
https://thepuissantlab.jimdo.com/

Description

A computational biologist position will be opened in March 2018 for three years (renewed each year) in the laboratory of research on molecular basis of Acute Myeloid Leukemia headed by an ERC / ATIP-AVENIR team leader Dr. Alexandre PUISSANT (https://thepuissantlab.jimdo.com/). The Puissant laboratory deciphers molecular mechanisms involved in leukemia development in pre-clinical mouse models of AML. Unbiased in vivo screening approaches are deployed in order to provide new therapeutic strategies to treat AML. Large-scale shRNA screening, genetic, biochemical, cell biological, as well as genome-wide approaches (WES, RNA-Seq, ChIP-Seq) are currently used in this lab.

The Puissant laboratory is housed at the Jean Bernard Center (INSERM U944) which is located at the Saint-Louis Hospital campus in Paris, France. The research developed in this institute encompasses a broad spectrum of fields, including cancer genomics, cancer biology and leukemia research. Most studies carried out in the unit have implications in translational research, together with clinical groups of the Saint-Louis Hospital. Our laboratory benefits from a direct access to the core facilities including: a recently extended animal facility, a sequencing facility (Mi-seq, Hi-seq, and Nextgen-seq technologies), and a flow core facility.

Selected Publications on the topic:
Fenouille N, Bassil CF, …, Puissant A. Creatine kinase pathway is a vulnerability in EVI1-positive Acute Myeloid Leukemia. Nat Med. In press.
Pikman Y, Puissant A, Alexe G, et al. Targeting MTHFD2 in acute myeloid leukemia. J Exp Med. 2016 Jun 27;213(7):1285-306. PMID: 27325891.
Puissant A, Fenouille N, Alexe G, et al. SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell. 2014 Feb 10;25(2):226-42. PMID: 24525236.
Miller PG, Al-Shahrour F, Hartwell KA, et al. In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. Cancer Cell. 2013 Jul 8;24(1):45-58. PMID: 23770013.
Puissant A, Frumm SM, Alexe G, et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013 Mar;3(3):308-23. PMID: 23430699.


Qualifications

We are looking for a highly motivated candidate with a strong background in data analysis, statistics and in programming in R and/or Python, and an extensive experience in NGS data analysis (RNA-seq, ChIP-seq, WES). In addition, the candidate should able to run comparative marker, GSEA, ssGSEA, EdgeR/RIGER, and ICA analyses, be familiar with the use of cBioPortal or MSigDB datasets, and be able to implement their data on GENE-E/Morpheus and IGV softwares. Applicants should hold a PhD degree in Computational Sciences or related disciplines (or have recently submitted their thesis with scheduled defense).


Start date

As soon as possible

How to Apply

Thanks to send your application (in French or English) to alexandre.puissant@inserm.fr by including in one single pdf file (applicantName_application2018.pdf):
− description of the main past achievements and skills of the candidate (max 2 pages);
− full Curriculum Vitae;
− contact details of three individuals who can be contacted for recommendation letters.


Contact

Alexandre Puissant
alexandre.puissant@inserm.fr